Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mix Vaccine and Standard Therapy in Lung Carcinoma
NCT02333474Phase 2Completed
- Sponsor
- Fuda Cancer Hospital
- Start
- Jan 2015
- Primary completion
- Aug 2015
- Modality
- Live Attenuated Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of measles virus vaccine live in lung carcinoma (2 arms), sponsored by Fuda Cancer Hospital. Primary endpoint: Efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 at 2 years. Started Jan 2015; status: completed.
02
Drugs
measles virus vaccine live
03
Conditions
lung carcinoma
Beyond the preview
Go deeper on NCT02333474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02333474.